High tumor necrosis factor-α/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C

Cytokine

Volumn 62, Issue 3, 2013, Pages 421-425

  Aroucha, D C B L ^a,b,c   Do Carmo, R F ^b,d   Moura, P ^b   Silva, J L A ^a   Vasconcelos, L R S ^c,d   Cavalcanti, M S M ^b   Muniz, M T C ^b   Aroucha, M L ^b   Siqueira, E R F ^c   Cahu G G O M ^a   Pereira, L M M B ^b,c   Coelho M R C D ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Instituto Do Figado and Transplants of Pernambuco   (Brazil)

^d Rede Nordeste de Biotecnologia (RENORBIO)   (Brazil)

Author keywords

Cytokine; HCC; HCV; IL 10; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; IL10 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; BLOOD; COMPLICATION; GENETICS; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS;

HEPATITIS C VIRUS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-10; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84877829154     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.03.024     Document Type: Article

References (44)

1. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14:1-21.
2. Shiffman M.L. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. Liver Transpl 2003, 9:S14-20.
3. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
4. Thorgeirsson S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
5. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
6. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48:S20-S37.
7. Wang Y.Y., Lo G.H., Lai K.H., Cheng J.S., Lin C.K., Hsu P.I. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003, 66:593-598.
8. Mondelli M.U., Barnaba V. Viral and host immune regulatory mechanisms in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2006, 18:327-331.
9. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1 associated cytokines. Hepatology 1996, 24:759-765.
10. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997, 25:449-458.
11. Larrea E., Garcia N., Qian C., Civeira M.P., Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996, 23:210-217.
12. Nelson D.R., Lim H.L., Marousis C.G., Fang J.W., Davis G.L., Shen L., et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997, 42:2487-2494.
13. Kuzushita N., Hayashi N., Katayama K., Kanto T., Oshita M., Hagiwara H., et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997, 32:169-174.
14. Bruix J., Sherman M. American association for the study of liver diseases. management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
15. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
16. Asselah T., Bièche I., Sabbagh A., Bedossa P., Moreau R., Valla D., et al. Gene expression and hepatitis C virus infection. Gut 2009, 58:846-858.
17. Ashfaq U.A., Javed T., Rehman S., Nawaz Z., Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011, 8:161.
18. Gigi E., Raptopoulou-Gigi M., Kalogeridis A., Masiou S., Orphanou E., Vrettou E., et al. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat 2008, 15:145-154.
19. Falasca K., Ucciferri C., Dalessandro M., Zingariello P., Mancino P., Petrarca C., et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006, 36:144-150.
20. Kakumu S., Okumura A., Ishikawa T., Yano M., Enomoto A., Nishimura H., et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease. Clin Exp Immunol 1997, 109:458-463.
21. Chau G.Y., Wu C.W., Lui W.Y., Chang T.J., Kao H.L., Wu L.H., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000, 231:552-558.
22. Abayli B., Canataroǧlu A., Akkiz H. Serum profile of T helper 1 and T helper 2 cytokines in patients with chronic hepatitis C virus infection. Turk J Gastroenterol 2003, 14:7-11.
23. Akcam F.Z., Tigli A., Kaya O., Ciris M., Vural H. Cytokine levels and histopathology in chronic hepatitis B and chronic hepatitis C. J Interferon Cytokine Res 2012, 32:570-574.
24. Talaat R.M., Esmail A.A., Elwakil R., Gurgis A.A., Nasr M.I. Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer 2012, 31:29-35.
25. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
26. Swia̧tek B.J. Is interleukin-10 gene polymorphism a predictive marker in HCV infection?. Cytokine Growth Factor Rev 2012, 23:47-59.
27. Nelson D.R., Lauwers G.Y., Lau J.Y., Davis G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000, 118:655-660.
28. Louis H., Le Moine O., Peny M.-O., Quertinmont E., Fokan D., Goldman M., et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 1997, 25:1382-1389.
29. Thompson K., Maltby J., Fallowfield J., Mcaulay M., Millward-Sadler H., Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998, 28:1597-1606.
30. Tarao K., Rino Y., Ohkawa S., Shimizu A., Tamai S., Miyakawa K., et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999, 86:589-595.
31. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
32. Yang Y., Luo C., Feng R., Bi S. The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2011, 137:947-952.
33. Ho S.Y., Wang Y.J., Chen H.L., Chen C.H., Chang C.J., Wang P.J., et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control 2004, 15:657-663.
34. Huang Y.S., Hwang S.J., Chan C.Y., Wu J.C., Chao Y., Chang F.Y., et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 1999, 62:327-333.
35. Neuman M.G., Benhamou J.P., Martinot M., Boyer N., Shear N.H., Malkiewicz I., et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clin Biochem 1999, 32:537-545.
36. Wang Y.Y., Lo G.H., Lai K.H., Cheng J.S., Lin C.K., Hsu P.I. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003, 66:593-598.
37. Avrǎmescu C.S., Comǎnescu V., Popescu S.N., Turculeanu A., Bǎlǎşoiu M., Popescu C.F., et al. Correlations among the serum levels of some interleukins and the histopathological aspects in chronic viral hepatitis C. Rom J Morphol Embryol 2008, 49:57-62.
38. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
39. Giannelli G., Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol 2005, 20:939-944.
40. Jeng J.E., Tsai J.F., Chuang L.Y., Ho M.S., Lin Z.Y., Hsieh M.Y., et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007, 9:987-992.
41. Bouzgarrou N., Hassen E., Gabbouj S., Schvoerer E., Ben Mami N., Triki H., et al. Lack of effect of tumor necrosis factor-alpha -308 G/A polymorphism on severity of liver fibrosis in Tunisian hepatitis C virus (HCV)-infected patients. Gastroenterol Clin Biol 2010, 34:297-304.
42. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
43. Othoro C., Lal A.A., Nahlen B., Koech D., Orago A.S., Udhayakumar V. A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis 1999, 179:279-282.
44. Kyriakidis I., Samara P., Papa A. Serum TNF-α, sTNFR1, IL-6, IL-8 and IL-10 levels in Weil's syndrome. Cytokine 2011, 54:117-120.